|
|
Search by color, shape and markings. click here
|
|
Check any 2 drugs for interactions. click here
|
|
|
Compare any two drugs side by side. click here
|
|
|
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
|
Reduction of urinary obstruction and relief of associated manifestations (e.g., hesitancy, terminal dribbling of urine, interrupted or weak stream, impaired size and force of stream, sensation of incomplete bladder emptying or straining) in hypertensive or normotensive patients with symptomatic BPH.
Although drug therapy usually is not as effective as surgical therapy, it may provide adequate symptomatic relief with fewer and less serious adverse effects compared with surgery.
May consider combined therapy with an α1-adrenergic blocker and 5α-reductase inhibitor for men with bothersome moderate to severe BPH and demonstrable prostatic enlargement. Has been more effective than therapy with either drug alone in preventing long-term BPH symptom progression. Men at risk for BPH progression are most likely to benefit from combination therapy.
Manufacturer states that tamsulosin should not be used for the treatment of hypertension.
Administer orally once daily, 30 minutes after the same meal each day.
Swallow capsules intact; do not open, crush, or chew capsules.
Available as tamsulosin hydrochloride; dosage expressed in terms of the salt.
Initially, 0.4 mg once daily. Allow 2–4 weeks to assess response at initial dosage. May increase dosage to 0.8 mg once daily, if necessary, to improve urinary flow rates and reduce symptoms.
If administration is interrupted for several days at either dosage (i.e., 0.4 or 0.8 mg daily), reinitiate therapy at dosage of 0.4 mg once daily.
Dosage adjustment not necessary in patients with moderate hepatic impairment.
Dosage adjustment not necessary in patients with mild to severe renal impairment (Clcr 10–70 mL/minute per 1.73 m2).
Not studied in patients with end-stage renal disease (Clcr <10 mL/minute per 1.73 m2).
Potential for postural hypotension, dizziness, or vertigo; syncope may occur.
Priapism reported rarely; treat promptly.
Rash, pruritus, urticaria, and angioedema of the tongue, lips, and face reported; positive rechallenge in some patients.
Allergic reaction to tamsulosin reported rarely in patients with sulfonamide sensitivity. Use with caution in patients with serious or life-threatening sulfonamide sensitivity.
Exclude possibility of prostate cancer prior to initiation of therapy.
IFIS observed during phacoemulsification cataract surgery in some patients receiving α1-blockers, including tamsulosin. Most cases were in patients who continued tamsulosin therapy at the time of cataract surgery.
Specifically question male patients being considered for cataract surgery to ascertain whether they have received tamsulosin or other α1-blockers. If patient has received tamsulosin, ophthalmologist should be prepared for possible modifications to his/her surgical technique (e.g., use of iris hooks, iris dilator rings, viscoelastic substances) to minimize complications of IFIS.
Benefit of discontinuing α1-blockers, including tamsulosin, prior to cataract surgery not established.
Category B. Not indicated for use in women.
Not indicated for use in women.
Not indicated for use in children.
No substantial differences in safety and efficacy relative to younger adults, but increased sensitivity cannot be ruled out.
Headache, infection, asthenia, back pain, chest pain, dizziness, somnolence, insomnia, decreased libido, rhinitis, pharyngitis, increased cough, sinusitis, diarrhea, nausea, tooth disorder, abnormal ejaculation, blurred vision.
Last Updated: November 01, 2007Related Learning Centers |